1. Homepage
  2. Equities
  3. Italy
  4. Borsa Italiana
  5. Recordati
  6. News
  7. Summary
    REC   IT0003828271

RECORDATI

(REC)
  Report
Delayed Borsa Italiana  -  11:35 2022-06-24 am EDT
41.86 EUR   +7.64%
06/20RECORDATI : Share buy-back program to service the stock option plans
PU
06/14RECORDATI : Ultima presentazione del gruppo
PU
06/14RECORDATI : Latest Company presentation
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Recordati confirms 2022 targets despite Ukraine conflict

05/10/2022 | 06:36am EDT

(Reuters) - Italian pharmaceutical group Recordati said on Tuesday it confirmed its 2022 financial targets despite the ongoing conflict in Ukraine, after posting a rise in sales and core earnings in the first three months of the year.

The Milan-based company, which operates in both Russia and Ukraine, said in a statement "the first quarter of 2022 was characterised by a general recovery in relevant markets" and that results were in line with the guidance set for the year.

Earnings before interests, taxes, depreciation and amortization (EBITDA) in the months to March were up 8.7% 163.0 million euros ($171.77 million), lifted by a 9% increase in net revenue.

($1 = 0.9489 euros)

(Reporting by Agnese Stracquadanio)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
RECORDATI 7.64% 41.86 Delayed Quote.-25.91%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) -1.63% 53.6 Delayed Quote.-27.29%
All news about RECORDATI
06/20RECORDATI : Share buy-back program to service the stock option plans
PU
06/14RECORDATI : Ultima presentazione del gruppo
PU
06/14RECORDATI : Latest Company presentation
PU
05/23RECORDATI : Ex-dividend day for final dividend
FA
05/18Alliance Pharma Chair to Step Down in 2023; Successor Named
MT
05/10Recordati Industria Chimica e Farmaceutica S.p.A. Reports Earnings Results for the Firs..
CI
05/10Recordati Industria Chimica Seeks M&A
CI
05/10TRANSCRIPT : Recordati Industria Chimica e Farmaceutica S.p.A., Q1 2022 Earnings Call, May..
CI
05/10Recordati Confirms 2022 Financial Targets
MT
05/10Recordati confirms 2022 targets despite Ukraine conflict
RE
More news
Analyst Recommendations on RECORDATI
More recommendations
Financials
Sales 2022 1 755 M 1 852 M 1 852 M
Net income 2022 383 M 404 M 404 M
Net Debt 2022 1 366 M 1 441 M 1 441 M
P/E ratio 2022 23,6x
Yield 2022 2,67%
Capitalization 8 606 M 9 078 M 9 078 M
EV / Sales 2022 5,68x
EV / Sales 2023 5,16x
Nbr of Employees 4 303
Free-Float 46,5%
Chart RECORDATI
Duration : Period :
Recordati Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RECORDATI
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Last Close Price 41,86 €
Average target price 46,38 €
Spread / Average Target 10,8%
EPS Revisions
Managers and Directors
Robert Koremans Chief Executive Officer
Luigi Felice la Corte Group Chief Financial Officer
Andrea Recordati Chairman
Raffaele Sabia Senior VP-Pharmaceutical Research & Development
Giovanni Minora Head-Group Audit & Compliance
Sector and Competitors
1st jan.Capi. (M$)
RECORDATI-25.91%9 078
JOHNSON & JOHNSON5.02%479 678
ELI LILLY AND COMPANY13.21%293 110
PFIZER, INC.-15.17%289 466
ROCHE HOLDING AG-15.91%272 090
ABBVIE INC.12.51%269 202